Topical Medications in Dermatology: Classes and Clinical Use

Topical medications form the first-line treatment framework for the majority of dermatologic conditions managed in outpatient settings across the United States. This page covers the principal drug classes applied directly to skin, their mechanisms of action, how clinicians select among them, and the regulatory and safety boundaries that govern their use. Understanding these categories is foundational to interpreting dermatology treatment plans, evaluating published clinical guidance, and navigating the broader regulatory context for dermatology that shapes prescribing practice.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

Topical medications in dermatology are pharmacologically active substances formulated for direct application to the skin surface, mucous membranes, or nail structures, with the intent of producing a local — and in some cases systemic — therapeutic effect. The U.S. Food and Drug Administration (FDA) regulates these agents under 21 CFR Parts 310–314 for new drug applications and under the Federal Food, Drug, and Cosmetic Act (FD&C Act), which distinguishes between over-the-counter (OTC) monograph drugs and prescription-only products.

The scope of topical dermatologic therapy spans inflammatory skin diseases such as eczema and atopic dermatitis and psoriasis, infectious conditions including fungal skin infections, proliferative disorders such as actinic keratosis and skin cancers, pigmentation disorders, and wound management. The National Institutes of Health (NIH) MedlinePlus drug database catalogs over 200 distinct topically applied dermatologic formulations available in the United States, encompassing prescription and OTC categories.

Core mechanics or structure

Skin penetration and vehicle science

The stratum corneum — the outermost layer of the epidermis, typically 10–20 micrometers thick in healthy adult skin — is the primary barrier that topical drugs must traverse. Drug penetration depends on three interacting variables: the physicochemical properties of the active molecule (molecular weight, lipophilicity, charge), the integrity of the barrier at the site of application, and the vehicle or base in which the drug is delivered.

Vehicles are classified by the American Academy of Dermatology (AAD) into several categories:

• Ointments — occlusive, petrolatum-based; highest potency delivery and moisturization
• Creams — oil-in-water or water-in-oil emulsions; intermediate occlusion
• Gels — water- or alcohol-based; rapid evaporation, good for hair-bearing and oily skin
• Lotions — low viscosity; large surface area application
• Foams and solutions — scalp and flexural area use; rapid spreading
• Patches and films — controlled-release delivery; prolonged contact time

The vehicle selection directly affects bioavailability of the active ingredient at the target skin layer. An ointment formulation of a corticosteroid can deliver 3–10 times the percutaneous absorption of an equivalent cream formulation of the same drug concentration, as documented in FDA product labeling comparisons for agents such as betamethasone dipropionate.

Causal relationships or drivers

Several factors determine which topical agent is selected for a given condition:

Disease pathophysiology: Inflammatory conditions driven by Th2 cytokine pathways (atopic dermatitis) respond to agents that suppress interleukin signaling; bacterial infections require antimicrobial agents with gram-positive coverage because Staphylococcus aureus colonizes affected skin in over 90% of atopic dermatitis patients, per research cited by the National Eczema Association.

Skin site: Thinner skin at the eyelids and genitals absorbs topical drugs at higher rates than palmar or plantar skin, requiring lower-potency formulations to prevent adverse effects.

Age: Pediatric patients have a higher body surface area-to-weight ratio, increasing systemic absorption risk from topical agents, a pharmacokinetic relationship recognized in FDA labeling for pediatric use restrictions on high-potency corticosteroids.

Comorbidities: Immunosuppressed patients, including those on biologic agents for systemic skin conditions, may face altered infection risk with topical immunomodulators.

Regulatory approval status: The FDA's drug approval database distinguishes agents approved for specific indications; off-label use is common in dermatology, particularly for retinoids and certain corticosteroids.

Classification boundaries

Topical dermatologic medications are classified by mechanism into seven major categories:

1. Corticosteroids: Divided into 7 potency classes (Class I = superpotent to Class VII = least potent) under the classification system widely referenced in the Journal of the American Academy of Dermatology. Examples range from clobetasol propionate 0.05% (Class I) to hydrocortisone 1% (Class VII).

2. Calcineurin inhibitors: Non-steroidal immunomodulators (tacrolimus, pimecrolimus). FDA-approved for atopic dermatitis; carry an FDA boxed warning regarding theoretical long-term malignancy risk, added in 2006 under the FDA's safety communication framework (21 CFR 201.57).

3. Retinoids: Vitamin A derivatives that normalize keratinocyte proliferation and differentiation. Topical forms include tretinoin, adapalene (OTC since 2016 in the U.S. at 0.1%), and tazarotene. Detailed coverage appears at retinoids in dermatology.

4. Antimicrobials: Topical antibiotics for skin conditions (mupirocin, clindamycin, erythromycin) and antifungals (clotrimazole, terbinafine, ciclopirox). Resistance surveillance is conducted through CDC's National Antimicrobial Resistance Monitoring System (NARMS).

5. Antineoplastics: 5-fluorouracil (5-FU) and imiquimod are FDA-approved for actinic keratosis and superficial basal cell carcinoma; these agents work via distinct mechanisms (pyrimidine antimetabolite vs. Toll-like receptor 7 agonist).

6. Vitamin D analogues and keratolytics: Calcipotriene targets psoriasis via vitamin D receptor-mediated inhibition of keratinocyte proliferation. Salicylic acid (2–40% concentrations) is classified as an OTC keratolytic under FDA monograph conditions.

7. Depigmenting agents: Hydroquinone 2% is available OTC; 4% requires a prescription. The FDA placed hydroquinone on the "not generally recognized as safe and effective" (GRASE) list in 2020, pending additional safety studies, under a proposed rule published in the Federal Register.

Tradeoffs and tensions

Topical therapy presents genuine clinical tensions that dermatologists must navigate:

Efficacy vs. safety window: Superpotent corticosteroids (Class I) clear inflammatory plaques faster than low-potency agents but carry documented risks of skin atrophy, telangiectasia, hypothalamic-pituitary-adrenal (HPA) axis suppression, and — with widespread application — systemic effects. The AAD's clinical practice guidelines for psoriasis specify duration and body surface area limits for Class I agents.

Steroid phobia and undertreatment: Published surveys in the Journal of the American Academy of Dermatology have documented that 36–72% of patients and caregivers report concerns about topical corticosteroid use that lead to subtherapeutic application, resulting in inadequately controlled disease flares.

Resistance pressure: Topical antibiotic monotherapy for acne vulgaris drives Cutibacterium acnes resistance. CDC guidance and the Global Antibiotic Resistance Partnership (GARP) both flag dermatologic antibiotic use as a resistance contributor, making combination therapy or non-antibiotic alternatives preferable for long-term management.

Vehicle tolerability vs. potency delivery: Patients frequently prefer aesthetically elegant vehicles (gels, lotions) over ointments, reducing occlusion and drug delivery. Adherence data from clinical trials consistently show that vehicle preference is a significant predictor of treatment success, independent of the active ingredient.

Regulatory classification limits: The FDA's distinction between cosmetic and drug claims (FD&C Act §201(g) vs. §201(i)) creates tension in the OTC market, where "cosmeceutical" is not a recognized legal category, and products marketed with drug-like claims require NDA or monograph compliance.

Common misconceptions

Misconception: Higher concentration always means stronger effect.
Concentration and potency class are separate variables. Hydrocortisone 2.5% is still Class VII (least potent); betamethasone dipropionate 0.05% in an augmented ointment is Class I. Potency class is determined by vasoconstrictor assay and pharmacokinetic data, not percentage alone.

Misconception: Topical drugs do not enter systemic circulation.
Percutaneous absorption is well-documented for multiple classes. Topical corticosteroids applied to large surface areas can suppress serum cortisol levels measurably. The FDA requires systemic pharmacokinetic studies for topical drugs applied over extended body surface areas under the guidance document "Topical Dermatological Drug Product NDAs and ANDAs — In Vivo Bioavailability, Bioequivalence, In Vitro Release, and Associated Studies" (FDA, 1998, updated guidance 2018).

Misconception: OTC status means unrestricted safe use.
OTC monograph drugs are approved for self-limiting conditions at specified concentrations and durations. Salicylic acid at concentrations above 2% for facial use or hydrocortisone used for longer than 7 days without medical supervision exceed monograph conditions and may trigger adverse outcomes, including salicylate toxicity or masked infections.

Misconception: Natural or plant-derived topicals are inherently safer.
Contact dermatitis and allergic sensitization occur with plant-derived ingredients including tea tree oil, lavender, and propolis. The American Contact Dermatitis Society's Core Allergen Series includes multiple botanical-derived compounds.

Checklist or steps (non-advisory)

The following represents the standard clinical decision sequence documented in AAD and FDA-aligned prescribing frameworks — not a treatment recommendation for any individual patient:

1. Identify the diagnosis and target skin layer — determine whether the pathology is epidermal, dermal, or subcutaneous; topical therapy is generally effective only to the upper dermis.
2. Assess the body site — document thickness, occlusion potential, and proximity to mucous membranes or eyes.
3. Select the appropriate drug class — match mechanism to disease pathophysiology (anti-inflammatory, antimicrobial, antiproliferative, keratolytic).
4. Select potency or concentration within class — apply regulatory potency classifications (7-class system for corticosteroids; FDA approval tiers for other agents).
5. Select the vehicle — consider disease type (wet vs. dry lesion), body site, patient age, and anticipated adherence.
6. Document the body surface area to be treated — required for safety calculations, particularly for corticosteroids and antineoplastics.
7. Review FDA labeling for pediatric, pregnancy, and duration restrictions — consult current FDA prescribing information via DailyMed (National Library of Medicine).
8. Document patient education elements — application technique, quantity (fingertip unit method), frequency, and stopping criteria per FDA-labeled instructions.
9. Schedule monitoring — HPA axis assessment for extended high-potency corticosteroid use; resistance monitoring for topical antibiotics per CDC-NARMS framework.

Reference table or matrix

Topical Dermatologic Drug Classes: Key Comparison

The home resource for dermatology topics provides navigational access to condition-specific pages that reference topical therapy in clinical context, including acne treatment, rosacea management, and vitiligo treatment options.

References

• U.S. Food and Drug Administration — DailyMed Drug Labeling Database
• FDA — Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §301 et seq.
• FDA — Guidance for Industry: Topical Dermatological Drug Products NDAs and ANDAs (1998, updated)
• American Academy of Dermatology — Clinical Practice Guidelines
• CDC — National Antimicrobial Resistance Monitoring System (NARMS)
• National Library of Medicine — MedlinePlus Drug Information
• FDA — Federal Register: Hydroquinone OTC Monograph Proposed Rule (2020)
• National Eczema Association — Eczema Facts
• [American Contact Dermatitis Society — Core Aller

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)